2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow Applied Molecular Evolution: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib LY2127399 - Multiple Myeloma | Phase 1 | Completed | Applied Molecular Evolution | 48 | 2008-03-01 | 2015-06-29 |
| Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma AME-133v (LY2469298) - Non-Hodgkin's Lymphoma | Phase 1 | Completed | Applied Molecular Evolution | 67 | 2006-07-01 | 2016-01-07 |
Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Recurrence (1)
ocaratuzumab (1) · tabalumab (1)
United States (2)
Andres Forero-Torres, MD (1) · Brad Pohlman, MD (1) · Brian Link, MD (1) · Ian Flinn, MD, PhD (1) · Kristen Ganjoo, MD (1) · Markus Mapara, MD, PhD (1) · Michael E. Williams, MD (1) · Mitchell R. Smith, MD, PhD (1) · Nam Dang, MD (1) · Stephanie A. Gregory, MD (1) · Susan Carpenter, PhD (1) · Sven de Vos, MD, PhD (1)